- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 90,930 | 26.06.24 17:35:54 | -0,280 | -0,31% | 0,000 | 0,000 | 91,910 | 91,210 |
|
Regeneron Pharmaceuticals | 881535 | NASDAQ | 1.068,890 | 26.06.24 21:44:50 | -2,300 | -0,21% | 1.068,090 | 1.069,070 | 1.068,120 | 1.071,190 |
